Leadership & Business Development Team

Working with the best in global pharmaceuticals

Our leadership team is committed to enhancing the success of our clients’ research and development activities; from uncovering novel targets and mechanisms of action, through to helping to select the best and safest drug candidates. We strive to maintain outstanding relationships with our clients and partners and deliver the highest quality of service.

Retrogenix has an experienced leadership team that is supported by a talented international business development team.

Dr Jim Freeth
Co-Managing Director
Jo Soden
Co-Managing Director
Mark Woodward
Investor Director and Business Consultant
Alex Kelly
US Business Development Manager
Dr Mark Aspinall-O’Dea
EMEA Business Development Manager
Dara Sandau
US Business Development
Dr Elizabeth Kingsley
Marketing and Scientific Communications
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
glycotope_logo
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Retrogenix helped us to crack a very challenging problem, the result of which has significantly advanced our research. A collaborative approach, alongside an in-depth scientific and technical knowledge of their technology turned an unsuccessful initial screen into an extremely successful secondary screen. We have already committed to further studies.
Dr. Nicky Cooper, CSO, Peptinnovate